

Xenon Pharmaceuticals Inc.
 Form 3
 November 04, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â COHEN CHARLES J. (Last) (First) (Middle) C/O XENON PHARMACEUTICALS INC.,Â 200 - 3650 GILMORE WAY (Street) BURNABY,Â A1Â V5G 4W8 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/04/2014	3. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) VP, Biology	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--	---	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: Xenon Pharmaceuticals Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â <u>(1)</u>	02/04/2018	Common Shares	26,748 <u>(2)</u>	\$ 3.71 <u>(3)</u>	D	Â
Stock Option (Right to Buy)	Â <u>(4)</u>	12/31/2018	Common Shares	4,115 <u>(2)</u>	\$ 3.07 <u>(3)</u>	D	Â
Stock Option (Right to Buy)	Â <u>(5)</u>	12/31/2019	Common Shares	3,600 <u>(2)</u>	\$ 3.56 <u>(3)</u>	D	Â
Stock Option (Right to Buy)	Â <u>(6)</u>	12/31/2020	Common Shares	2,057 <u>(2)</u>	\$ 3.76 <u>(3)</u>	D	Â
Stock Option (Right to Buy)	Â <u>(7)</u>	12/31/2021	Common Shares	2,057 <u>(2)</u>	\$ 3.67 <u>(3)</u>	D	Â
Stock Option (Right to Buy)	Â <u>(8)</u>	12/31/2022	Common Shares	3,086 <u>(2)</u>	\$ 2.68 <u>(9)</u>	D	Â
Stock Option (Right to Buy)	Â <u>(10)</u>	01/13/2024	Common Shares	4,115 <u>(2)</u>	\$ 9.85 <u>(11)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
COHEN CHARLES J. C/O XENON PHARMACEUTICALS INC. 200 - 3650 GILMORE WAY BURNABY, Â A1Â V5G 4W8	Â	Â	Â VP, Biology	Â

Signatures

/s/ Barbara Mery, Attorney-in-fact for Charles J. Cohen

11/04/2014

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares subject to the option fully vested on February 5, 2012.
- (2) Reflects a 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split").
The exercise price was converted from \$3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- (4) The shares subject to the option fully vested on January 1, 2013.
- (5) The shares subject to the option fully vested on January 1, 2014.
- (6) 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2011 Vesting Commencement

Edgar Filing: Xenon Pharmaceuticals Inc. - Form 3

Date.

(7) 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2012 Vesting Commencement Date.

(8) 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2013 (the "2013 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2013 Vesting Commencement Date.

(9) The exercise price was converted from \$2.67 CDN using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

(10) 25% of the shares subject to the Option vest on the one year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2014 Vesting Commencement Date.

(11) The exercise price was converted from \$10.78 CDN using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.